Stanley Jordan MD, FASN, FAST

Cedars Sinai Medical Center

Dr. Jordan is Director of Kidney Transplantation and Transplant Immunology at the Kidney and Pancreas Transplant Center at Cedars Sinai, and Director of the Division of Pediatric and Adult Nephrology.

Research directed by Stanley C. Jordan, MD, has led to major advances in diagnostic and treatment approaches in the care of patients receiving transplanted organs.

He developed a process that uses intravenous immunoglobulin (IVIG) to reduce the risk of rejection in difficult cases in which other medications have failed. He also created a technique to detect post-transplant lymphoproliferative disorder (PTLD) in its earliest stages, when intervention is most effective. (PTLD is a form of cancer that can have catastrophic effects on children who receive donated organs.)

For more than two decades, Dr. Jordan has performed extensive research into various aspects of immunology and transplantation, funded by dozens of research grants and awards, including two prestigious National Institutes of Health controlled clinical trials in kidney transplantation grants. He has written hundreds of articles and abstracts published in scientific journals, presented findings at medical and scientific organizations and authored about two dozen book chapters.

He was appointed in 1998 to a task force assembled by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to advise Congress on the safety and efficacy of intravenous gammaglobulin products. He also served on another NIH/NIAID task force that was commissioned to develop research priorities for kidney transplantation for the 21st century. Among his numerous other appointments, he was a member of the American Society of Transplant Physicians/American Society of Transplant Surgeons task force on transplant tolerance induction in 1997.